Pharma News

United by inequity: The healthcare disparities plaguing rare disease patients and Black Americans

This audio is auto-generated. Please let us know if you have feedback.

When Tamar Thompson’s husband was diagnosed with prostate cancer, she knew better than most what kinds of testing and care he’d need. As vice president and head of corporate affairs at Alexion, AstraZeneca Rare Disease, Thompson is intimately familiar with the healthcare world. And as a decorated officer in the United States Air Force, her husband should have received the best, most cutting-edge care.

Despite all these advantages, Thompson still struggled to get her husband the genetic testing she knew was available.

“I had to fight for that. It wasn’t offered right up front,” she said. “I don’t know that it would have been (like) for someone who was non-African American. But I know that for him, I had to fight for a number of things. And thank goodness I work in the space to know what to ask for. But I saw the misses along the way.”

Thompson even pulled her husband out of their local health system for fear that he wouldn’t get adequate care as a Black man.

These challenges — including lack of access, missed care and subpar treatment at small or rural hospitals — are common healthcare experiences for people of color.

They’re also common for rare disease patients, and Thompson sees those parallels every day.

For instance, rare disease patients often live in rural communities without access to an academic medical center, she said, and that’s true for minority patients, too.

“Black and brown patients generally can’t travel more than a 50-to-75-mile radius from their home,” she said.

“I’ve never looked back. I’m still loving every minute of it and appreciating the opportunity and the privilege that I get to come in every day and search for disease patients.”

Tamar Thompson

VP, head of corporate affairs, Alexion, AstraZeneca Rare Disease

They often face similar financial hurdles, too.

“Rare disease patients live on one income, often because one person has had to give up a job to be a caregiver. And that’s very similar to some of the challenges you see in the minority communities as well,” she said.

Those parallels are some of the reasons why Thompson was drawn to working with the rare disease patient population at Alexion.

An unconventional path

A rare disease biopharma company that was acquired by AstraZeneca in July 2021, Alexion has five approved medications for seven rare diseases, including the blockbuster first-in-class C5 complement inhibitor Soliris (which was, at one time, the most expensive drug in the U.S.), and the second-generation C5 complement inhibitor Ultomiris. Its pipeline also consists of potential medicines for more than a half dozen rare therapeutic areas, including hematology, neurology, cardiology, nephrology, bone metabolism, metabolics and ophthalmology. 

Thompson leads the government affairs and policy and communications functions for the company, working to amplify the voices and experiences of rare disease patients, advocate for needed policy changes, create access opportunities for patients and partner with rare disease organizations.

Prior to joining Alexion in 2019, she worked as the head of federal executive branch strategy and state government affairs for Bristol Myers Squibb. However, her path to healthcare policy was much more unconventional.

At first, Thompson studied nursing, but soon realized that she wasn’t quite suited for it. Sticking a needle in someone’s arm and telling them, “Suck it up, buttercup? That probably isn’t the best bedside manner,” she laughed.

Instead, she shifted her focus to healthcare administration and the revenue cycle side of healthcare, eventually pivoting to the life sciences and policy advocacy. But it was working at Bristol Myers Squibb that first exposed her to the rare disease community and opened her eyes to the parallels between the experiences of rare disease patients and the healthcare inequities that minority communities face.

For instance, she notes that it often takes rare disease patients five to seven years to get a diagnosis, and that missed or delayed diagnoses are also common among ethnic minorities. Such diagnostic disparities are well documented in academic research, from dementia, to autism spectrum disorder, to appendicitis, to breast cancer and many other conditions.

Too often, health complaints of people in the Black community — especially Black women — are dismissed, Thompson said. In fact, she had a close family member who died from a disease because they didn’t get a diagnosis until it was too late.

That’s why, when she had the opportunity to move to Alexion and advocate on behalf of the rare disease community, she took it.

Source link
#United #inequity #healthcare #disparities #plaguing #rare #disease #patients #Black #Americans

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *